- My Alerts
- Go Ad-Free
-
My Account
In App
BSE Live
Aug 16, 16:00Prev. Close
0.51
Open Price
0.51
Bid Price (Qty.)
0.51 (100)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Balance Sheet of Vardhman Lab (in Rs. Cr.) | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | |
| Total Share Capital | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | |
| Reserves and Surplus | -2.13 | -2.09 | -2.05 | -2.02 | -1.99 | |
| Total Reserves and Surplus | -2.13 | -2.09 | -2.05 | -2.02 | -1.99 | |
| Total Shareholders Funds | 2.00 | 2.04 | 2.08 | 2.11 | 2.13 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade Payables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Current Liabilities | 0.03 | 0.01 | 0.02 | 0.00 | 0.01 | |
| Short Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Liabilities | 0.03 | 0.01 | 0.02 | 0.00 | 0.01 | |
| Total Capital And Liabilities | 2.03 | 2.05 | 2.10 | 2.11 | 2.14 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade Receivables | 1.56 | 1.56 | 1.55 | 1.55 | 1.90 | |
| Cash And Cash Equivalents | 0.43 | 0.48 | 0.53 | 0.54 | 0.23 | |
| Short Term Loans And Advances | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
| OtherCurrentAssets | 0.03 | 0.00 | 0.01 | 0.02 | 0.00 | |
| Total Current Assets | 2.03 | 2.05 | 2.10 | 2.11 | 2.14 | |
| Total Assets | 2.03 | 2.05 | 2.10 | 2.11 | 2.14 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | -- | -- | -- | -- | -- | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
15.03.2026
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth
